NBP PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

NBP ▼ -51.21% at T+60d

LONG call ✗ call lost -51.21% · α vs SPY -63.20% · entry $3.51 → $1.71

Last close $1.56 (close Jun 8) · -55.49% from $3.51 entry

Entry anchored
Mar 6, 03:59 PM ET
via Databento tick

T+1d

-7.56%

call -7.56% · α -7.38%

$3.24

settled 3mo ago

T+5d

-17.26%

call -17.26% · α -15.91%

$2.90

settled 3mo ago

T+20d

-29.24%

call -29.24% · α -26.44%

$2.48

settled 2mo ago

T+60d

-51.21%

call -51.21% · α -63.20%

$1.71

settled 7d ago

Price Chart

Loading chart...

Executive Summary

NovaBridge Biosciences announced positive topline Phase 2a results for VIS-101, a dual VEGF-A X ANG-2 inhibitor, showing rapid, robust, and durable treatment responses in wet AMD with mean BCVA gains >10 ETDRS letters and median CST reductions of 100–150 µm. Nearly half of patients remained retreatment-free at 6 months, with a favorable safety profile and no dose-limiting toxicity. The data support advancement to a Phase 2b study in H2 2026 and a global Phase 3 program in 2027.

Actionable Insight

Traders should monitor upcoming Phase 2b trial initiation and design details, as well as competitive dynamics with faricimab (VEGF-A/ANG-2 inhibitor from Roche). Positive Phase 3 readout could significantly re-rate NBP stock; consider positioning ahead of clinical milestones.

Key Facts

VIS-101 demonstrated mean BCVA improvement of >10 ETDRS letters in wet AMD patients
Median CST reduction of 100–150 µm observed
Approximately two-thirds of patients were retreatment-free at 4 months; half at 6 months
No dose-limiting toxicity; 0% treatment-related adverse events in 3 mg group, 8% in 6 mg group
Phase 2b dose-finding study expected to begin in H2 2026, global Phase 3 in 2027

Financial Impact

Potential blockbuster value given best-in-class durability profile in a $10B+ ophthalmology market; could command premium pricing and high market share if Phase 3 confirms results

enterprise valuefuture revenuemarket shareR&D valuation

Risk Factors

Phase 2a was small (n=38) and conducted only in China; results may not replicate in larger, global populations
No direct comparison to current standard-of-care (e.g., faricimab) in the trial
Regulatory path remains uncertain; Phase 3 design and endpoints not yet disclosed

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3251682

6 reports for NBP

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +6.12%Apr 7, 2026

Filters

Reports for NBP — sortable, filterable
	Type				Now
Apr 22, 2026 6w ago	6-K NEUTRAL ★ 4/10	$2.58 $1.68	▼ −34.88%	▼ −38.05%	$1.56 (−39.53%)
Apr 7, 2026 9w ago	6-K BULLISH ★ 8/10	$2.45 $2.38	▼ −2.86%	▼ −11.40%	$1.56 (−36.33%)
Apr 7, 2026 9w ago	Press Release BULLISH ★ 8/10	$2.45 $2.38	▼ −2.86%	▼ −11.40%	$1.56 (−36.33%)
Apr 7, 2026 9w ago	20-F BULLISH ★ 8/10	$2.45 $2.38	▼ −2.86%	▼ −11.40%	$1.56 (−36.33%)
Mar 9, 2026 13w ago	Press Release BULLISH ★ 8/10	$3.51 $2.48	▼ −29.24%	▼ −26.44%	$1.56 (−55.49%)
Mar 3, 2026 14w ago	Press Release NEUTRAL ★ 5/10	$3.20 $2.46	▼ −23.13%	▼ −18.72%	$1.56 (−51.25%)

US Market Status

Market Closed — Opens in 7h 21m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access